A recent article in the Harvard Gazette suggests dance as a potential treatment for neurodegenerative disorders such as Parkinson’s disease (PD). Imaging studies have identified several brain regions involved in the complex, rhythmical, and coordinated movements that constitute dance. The motor cortex is — as with other kinds of voluntary…
A new study from the German Center for Neurodegenerative Diseases, published in the journal BRAIN, sheds new light on the processes leading to aggregation of the protein αlpha-synuclein in the brain of patients with Parkinson’s disease (PD). It has been proposed that the aggregates propagate in a fashion similar to prions,…
Contrary to recent evidence, new research has found no positive correlation between anticholinergic medication intake and a higher risk for dementia in Parkinson’s disease (PD) patients. The study is titled “Anticholinergic Load: Is there a Cognitive Cost in Early Parkinson’s Disease?” and appears in the Journal…
Evidence has shown a potential connection between chronic hepatitis C virus (HCV) infection and neurological and psychiatric disorders such as Parkinson’s disease (PD). In a recent study, investigators sought to determine if the disease was, in fact, a significant risk factor for Parkinson’s development. Their findings, in a study…
A recent study shows that patients with Parkinson’s disease (PD) have a dysfunctional brain reward anticipation response — a finding likely linked to the decreased motivational state that can afflict PD patients. The deficit in dopaminergic signaling that underlies PD affects more than just motor skills. Depression, apathy, and sleep disorders also frequently…
Parkinson’s News Today regularly reports the latest news on clinical trials, state-of-the-art research, and events related to Parkinson’s disease. With 2015 at a close, Parkinson’s News Today brings you the past year’s Top 10 Parkinson’s Disease Stories as determined by the number of views given each article by readers. No.
Amarantus BioScience Holdings, Inc. (AMBS) received a Notice of Allowance from the U.S. Patent and Trademark Office covering the use of 5HT1A in combination with 5HT1B agonists, including the clinical Phase 2b stage drug eltoprazine, to treat levodopa-induced dyskinesia (PD-LID) in Parkinson’s disease (PD). The office issues such a…
University of Nebraska Medical Center and Longevity Biotech researchers demonstrated that LBT-3627, a novel drug candidate developed by the company, prevented nerve cell damage and protected dopamine-producing cells in a mouse model of Parkinson’s disease. The research paper, entitled “Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in…
International Stem Cell Corporation announced that its subsidiary, Cyto Therapeutics, has been given regulatory permission to start a Phase 1/2a dose escalation clinical trial of its neural stem cells (ISC-hpNSC) in the treatment of Parkinson’s disease (PD). Clearance for the trial came the Therapeutics Goods Administration (TGA) of Australia. The trial will test…
A novel physiological role for mitochondria with implications in the study of age-related diseases such as Parkinson’s has been described. Researchers found that mitochondrial dysfunction in proliferating human cells induces senescence growth arrest and causes cells to secrete distinct secretory phenotypes. The research paper, titled “Mitochondrial Dysfunction Induces Senescence with a Distinct…
Get regular updates to your inbox.
